Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation

Japanese Journal of Cancer Research

Volumn 87, Issue 1, 1996, Pages 98-104

  Shibata, Toru ^a   Shibamoto, Yuta ^a   Sasai, Keisuke ^a   Oya, Natsuo ^a   Murata, Rumi ^a   Takagi, Takehisa ^a   Hiraoka, Masahiro ^a   Abe, Mitsuyuki ^b  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

Hypoxia; KU 2285; Radiation; Sensitizer; Tirapazamine

Indexed keywords

2,2 DIFLUORO N (2 HYDROXYETHYL) 3 (2 NITRO 1 IMIDAZOLYL)PROPIONAMIDE; RADIOSENSITIZING AGENT; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL KILLING; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; HYPOXIC CELL; INTRAPERITONEAL DRUG ADMINISTRATION; IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION;

EID: 0030066696     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1996.tb00206.x     Document Type: Article

References (43)

1. Thomlinson, R. H. and Gray, L. H. The histological structure of some human lung cancers and possible implications for radiotherapy. Br. J. Cancer, 9, 539-549 (1955).
2. Dische, S. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother. Oncol., 3, 97-115 (1985).
3. Overgaard, J. Sensitization of hypoxic tumour cells - clinical experience. Int. J. Radiat. Biol., 56, 801-811 (1989).
4. Brown, J. M. Evidence for acutely hypoxic cells in mouse tumors and a possible mechanism of reoxygenation. Br. J. Cancer, 52, 650-656 (1979).
5. Moulder, J. E. and Rockwell, S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys., 10, 695-712 (1984).
6. Kallman, R. F. and Dorie, M. J. Tumor oxygenation and reoxygenation during radiation therapy: their importance in predicting tumor response. Int. J. Radiat. Oncol. Biol. Phys., 12, 681-685 (1986).
7. Chaplin, D. J., Olive, F. L. and Durand, R. E. Intermittent blood flow in a murine tumour: radiobiological effects. Cancer Res., 47, 597-661 (1987).
8. 2 tension measurements. Cancer Res., 51, 3316-3322 (1991).
9. Chapman, J. D., Franko, A. J. and Sharplin, J. A marker for hypoxic cells with potential clinical applicability. Br. J. Cancer, 43, 546-550 (1981).
10. 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br. J. Cancer, 65, 90-95 (1992).
11. Dische, S. A review of hypoxic cell radiosensitization. Int. J. Radiat. Oncol. Biol. Phys., 20, 147-152 (1991).
12. Overgaard, J., Sand Hansen, H., Lindeløv, B., Overgaard, M., Jørgensen, K., Rasmusson, B. and Berthelsen, A. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother. Oncol., 20 (Suppl.), 143-149 (1991).
13. Hill, R. P., Gulyas, S. and Whitmore, G. F. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069. Br. J. Cancer, 53, 743-751 (1986).
14. Shibamoto, Y., Nishimoto, S., Shimokawa, K., Hisanaga, Y., Zhou, L., Wang, J., Sasai, K., Takahashi, M., Abe, M. and Kagiya, T. Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers. Int. J. Radiat. Oncol. Biol. Phys., 16, 1045-1048 (1989).
15. Sasai, K., Nishimoto, S., Shimokawa, K., Hisanaga, Y., Kitakabu, Y., Shibamoto, Y., Zhou, L., Wang, J., Takahashi, M., Kagiya, T. and Abe, M. A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys., 20, 1249-1254 (1991).
16. Shibamoto, Y., Streffer, C., Sasai, K., Oya, N. and Abe, M. Radiosensitization efficacy of KU-2285, RP-170, and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay. Int. J. Radiat. Biol., 61, 473-478 (1992).
17. Shibata, T., Shibamoto, Y., Oya, N., Sasai, K., Murata, R., Ishigaki, T. and Abe, M. Comparison of radiosensitizing effect of KU-2285 and SR-2508 at low drug concentrations and doses. Int. J. Radiat. Oncol. Biol. Phys., 29, 587-590 (1994).
18. Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K. and Lee, W. W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12, 1239-1242 (1986).
19. Baker, M. A., Zeman, E. M., Hirst, V. K. and Brown, J. M. Metabolism of SR 4233 by Chinese hamster ovary cells: the basis of selective hypoxic cytotoxicity. Cancer Res., 48, 5947-5952 (1988).
20. Zeman, E. M., Hirst, V. K., Lemmon, M. J. and Brown, J. M. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother. Oncol., 12, 209-218 (1988).
21. Brown, J. M. and Lemmon, M. J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res., 50, 7745-7749 (1990).
22. Zeman, E. M. and Brown, J. M. Aerobic radiosensitization by SR 4233 in rodent and human cells: mechanistic and therapeutic implications. Int. J. Radiat. Biol., 59, 117-131 (1991).
23. Brown, J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer, 67, 1163-1170 (1993).
24. Adams, G. E. and Stratford, I. J. Bioreductive drugs for cancer therapy: the search for tumor specificity. Int. J. Radiat. Oncol. Biol. Phys., 29, 231-238 (1994).
25. Brown, J. M. and Giaccia, A. J. Tumour hypoxia: the picture has changed in the 1990s. Int. J. Radiat. Biol., 65, 95-102 (1994).
26. Minchinton, A. I., Lemmon, M. J., Tracy, M., Pollart, D. J., Martinez, A. P., Tosto, L. M. and Brown, J. M. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive antitumor agents: pharmacology and activity in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys., 22, 701-705 (1992).
27. Doherty, N., Hancock, S. L., Kaye, S., Coleman, C. N., Shulman, L., Marquez, C., Mariscal, C., Rampling, R., Senan, S. and Roemeling, R. V. Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int. J. Radiat. Oncol. Biol. Phys., 29, 379-382 (1994).
28. Sasai, K., Fushiki, M., Yukawa, Y., Suyama, S., Iwai, H., Shibamoto, Y., Nishimoto, S., Takahashi, M. and Abe, M. In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation. Int. J. Radiat. Oncol. Biol. Phys., 21, 1231-1234 (1991).
29. Oya, N., Shibamoto, Y., Sasai, K., Sugiyama, T. and Abe, M. In vivo radiosensitization efficacy of KU-2285 and etanidazole at clinically relevant low radiation doses. Int. J. Radiat. Oncol. Biol. Phys., 27, 1113-1119 (1993).
30. Sasai, K., Iwai, H., Yoshizawa, T., Nishimoto, S., Shibamoto, Y., Kitakabu, Y., Oya, N., Takahashi, M. and Abe, M. Phannacokinetics of fluorinated 2-nitroimidazole hypoxic cell radiosensitizers in murine peripheral nervous tissue. Int. J. Radiat. Biol., 62, 221-227 (1992).
31. Shibamoto, Y., Yukawa, Y., Tsutsui, K., Takahashi, M. and Abe, M. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn. J. Cancer Res., 77, 908-915 (1986).
32. Kitakabu, Y., Shibamoto, Y., Sasai, K., Ono, K. and Abe, M. Variations of the hypoxic fraction in the SCCVII tumors after single dose and during fractionated radiation therapy: assessment without anesthesia or physical restraint of mice. Int. J. Radiat. Oncol. Biol. Phys., 20, 709-714 (1991).
33. Shibamoto, Y., Nishimura, Y., Nishidai, T., Takahashi, M. and Abe, M. Reoxygenation after a single dose of 15 Gy in the EMT6/KU sarcoma. Nippon Acta Radiol., 46, 1319-1323 (1986).
34. Shibamoto, Y., Sasai, K. and Abe, M. The radiation response of SCCVII tumor cells in C3H/He mice varies with the irradiation conditions. Radiat. Res., 109, 352-354 (1987).
35. Durand, R. E. and Olive, P. L. Evaluation of bioreductive drugs in multicell spheroids. Int. J. Radiat. Oncol. Biol. Phys., 22, 689-692 (1992).
36. Brown, J. M. and Lemmon, M. J. SR4233: a tumor specific radiosensitizer active in fractionated radiation regimes. Radiother. Oncol., 20 (Suppl.), 151-156 (1991).
37. Zeman, E. M., Lemmon, M. J. and Brown, J. M. Aerobic radiosensitization by SR4233 in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys., 18, 125-132 (1990).
38. Abe, M. and Takahashi, M. Intraoperative radiotherapy: Japanese experience. Int. J. Radiat. Oncol. Biol. Phys., 7, 863-868 (1981).
39. Abe, M. Intraoperative radiotherapy - past, present, and future. Int. J. Radiat. Oncol. Biol. Phys., 10, 1987-1990 (1984).
40. Hill, R. P. Sensitizers and radiation dose fractionation: results and interpretations. Int. J. Radiat. Oncol. Biol. Phys., 12, 1049-1054 (1986).
41. Shibamoto, Y., Kitakabu, Y., Murata, R., Oya, N., Shibata, T., Sasai, K., Takahashi, M. and Abe, M. Reoxygenation in the SCCVII tumor after KU-2285 sensitization plus single or fractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys., 29, 583-586 (1994).
42. Kim, I. H. and Brown, J. M. Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int. J. Radiat. Oncol. Biol. Phys., 29, 493-497 (1994).
43. Zwi, L. J., Baguley, B. C., Gavin, J. B. and Wilson, W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J. Natl. Cancer Inst., 81, 1005-1013 (1989).